On paper it sounds nice.
Our drug development strategy includes
Oncology, Hematology, Virology, Microbiology, Ophthalmology and Dermatology.
lol my head is spinning, what is next ?
Except Oncology (I think its safe to say now we can discard clinical work in dermatology as it is useless) everything else is pre-clinical and some of this preclinical work started 4 years ago and we are still struck in pre-clinical stage.
Answer to this question is "we are maximizing shareholder value" and anything less than $10B is not an acceptable offer. LMAO.